Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 66 publications.

Earnshaw S, Brogan AJ, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues - virtual. Presentation to be given at the 2024 Virtual ISPOR Short Course Program; December 4, 2024. Previously presented at the 2015 ISPOR 20th Annual International Meeting.

Brodtkorb TH, Knight C, Kamgar F, Teitsson S, Kurt M, Patel MY, Poretta T, Mamtani R, Palmer S. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective1. J Med Econ. 2024 Apr 4;27(1):543-53. doi: 10.1080/13696998.2024.2329019

Teittson S, Brodtkorb T-H, Kurt M, Patel M, Poretta T, Knight C, Kamgar F, Palmer S. Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. J Med Econ. 2024 Jan;27(1):473-81. doi: 10.1080/13696998.2024.2322394

Lanne G, Kinderås M, Ling C, Brodtkorb TH. How much does TLV value rarity? A review of reimbursement decisions on orphan drugs in Sweden from 2017 through 2022. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S201. doi: 10.1016/j.jval.2023.09.1028

Eriksson M, Andersson Galijatovic E, Schiel A, Brodtkorb T-H. The FINOSE collaboration – joint health technology assessment in the Nordics. Presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark.

Brodtkorb T-H, Brogan A, Davis A, Earnshaw S. Budget impact analysis II: applications and design issues. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the 2022 Virtual ISPOR Short Course Program.

Earnshaw S, Brodtkorb T-H, Mullins D. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the ISPOR 18th Annual European Congress.

Kamgar F, Ho S, Hawe E, Brodtkorb TH. A review of treatment effect waning methods for immuno-oncology therapies in National Institute for Health and Care Excellence technology appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S98. doi: 10.1016/j.jval.2022.09.476

Kamgar F, Thybo SH, Johannesen K, Teitsson S, Brodtkorb TH. Cost-effectiveness of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence with tumor cell pd-l1 expression ≥ 1% in Denmark. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.706

Kamgar F, Johannesen K, Thybo SH, Teittson S, Brodtkorb TH. Cost-effectiveness of nivolumab for the adjuvant treatment of muscle-invasive urothelial carcinoma patients with high risk of recurrence and tumor cell pd-l1 expression ≥ 1% in Sweden. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.707

Hancock H, Brockbank J, Theodorou E, Brodtkorb TH. Survival analysis methods used in immuno-oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S92. doi: 10.1016/j.jval.2022.09.451

Hancock H, Brockbank J, Brodtkorb TH, Lucherini S, Russell J. A review of cure assumptions implemented in early-stage oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S148. doi: 10.1016/j.jval.2022.09.714

Brodtkorb TH. Does the choice of cost-effectiveness model approach matter? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.

Earnshaw S, Brogan A, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2022 Virtual ISPOR Short Course Program; September 21, 2022. Previously presented at the 2021 Virtual ISPOR Short Course Program.

Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382

Earnshaw S, Brogan AJ, Brodtkorb T-H, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2021 Virtual ISPOR Short Course Program; December 6, 2021. Previously presented at the ISPOR 20th Annual International Meeting.

Hagberg K, Brodtkorb T-H. Patient-reported benefits of bone-anchored transfemoral prostheses as assessed by MedTech20 ©: a general outcome measure for medical products. Prosthet Orthot Int. 2021 Aug 1;45(4):355-61.

Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4

Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Poster presented at the 2021 Virtual AMCP; April 12, 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting.

Brodtkorb T-H, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HER2-overexpressed/amplified HR+ breast cancer who initiated neratinib within 1 year of completing trastuzumab in the U.S. Poster presented at the 2021 Virtual AMCP; April 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS).

Brockbank J, Krause T, Moss E, Pedersen AM, Morup MF, Ahdesmaki O, Vaughan J, Brodtkorb T-H. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review. Health Qual Life Outcomes. 2021 Mar 18;19(1):94. doi: 10.1186/s12955-021-01723-x

Earnshaw SR, Mauskopf JA, Mullins CD, Brodtkorb T-H. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Virtual Short Course Progam; February 3, 2021. Previously presented at the 2015 ISPOR 18th Annual European Congress.

Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H, Ling C, Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.

Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of HER2+ metastatic breast cancer in the United States. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.

Brodtkorb TH, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.

Mullins CD, Earnshaw SR, Brodtkorb T-H. Budget impact analysis I - A 6-step approach. Presented at the 2020 ISPOR Virtual Conference; June 18, 2020.

Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700

Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. The budget impact of introducing tildrakizumab to a United States health plan for managing moderate-to-severe plaque psoriasis. Pharmacoeconomics. 2020 Mar 26.

Aronsson M, Ling C, Stevenson A, Brodtkorb TH. Submission process and requirements of Nordic health technology assessment (HTA) authorities for hospital drugs - implications for market access strategy. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II - applications & design issues. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 20th Annual International Meeting.

Mullins CD, Earnshaw SR, Brodtkorb TH. Budget impact analysis I: a 6-step approach. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 18th Annual European Congress.

Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1

Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb TH, Mendelsohn AB, Lowry S, Wu JJ, Feldman SR, Armstrong AW. Budget-impact and cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis from a US health plan perspective. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2019 ISPOR 24th Annual International Meeting; May 19, 2019. New Orleans, LA. Previously presented at the ISPOR 20th Annual International Meeting.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness of tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.

Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. Budget impact of introducing tildrakizumab for the treatment of moderate to severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):s78.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II – applications and design issues. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 20, 2018. Baltimore, MD. Previously presented at the ISPOR 20th Annual International Meeting.

Hansson E, Hagberg K, Cawson M, Brodtkorb TH. Patients with unilateral transfemoral amputation treated with a percutaneous osseointegrated prosthesis. Bone Joint J. 2018 Apr 1;100-B(4):527-34.

Earnshaw SR, Mullins CD, Brodtkorb TH. Budget impact analysis I: a 6-step approach. Presented at the 2017 ISPOR 20th Annual European Congress; November 5, 2017. Glasgow, Scotland. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2017 ISPOR 20th Annual European Congress; November 5, 2017. Glasgow, Scotland. Previously presented at the ISPOR 20th Annual International Meeting.

Brodtkorb TH, Mauskopf J, Earnshaw SR. Estimating the treatment mix. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.59-69. doi: 10.1007/978-3-319-50482-7

Brodtkorb TH, Earnshaw SR, Mauskopf J. Estimating treatment-related costs. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.71-90. doi: 10.1007/978-3-319-50482-7

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 21, 2017. Boston, MA. Previously presented at the ISPOR 20th Annual International Meeting.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 20th Annual International Meeting.

Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 21st Annual International Meeting; May 22, 2016. Washington, DC. Previously presented at the ISPOR 20th Annual International Meeting.

Laramee P, Bell M, Irving A, Brodtkorb TH. The cost-effectiveness of the integration of nalmefene within the UK healthcare system treatment pathway for alcohol dependence. Alcohol Alcohol. 2016 May;51(3):283-90. doi: 10.1093/alcalc/agv140

Brodtkorb TH, Bell M, Irving AH, Laramee P. The cost effectiveness of nalmefene for reduction of alcohol consumption in alcohol-dependent patients with high or very high drinking-risk levels from a UK societal perspective. CNS Drugs. 2016 Feb;30(2):163-77. doi: 10.1007/s40263-016-0310-2